HALIX is gearing up for the future and significantly increases its capacity by building a new, highly efficient facility for biopharmaceutical products.
HALIX will serve new and existing B2B customers, as an end-to-end service provider, from the first development steps to start of commercial production after successful registration of products. For this purpose design and construction activities have started for a new 6.700 m² pharmaceutical facility with development and production clean rooms, in the centre of the Leiden Bio Science Park with over 100 companies in the Bioscience sector in the immediate vicinity.
HALIX is a corporate venture and a spin-off of HAL Allergy, based in Leiden (The Netherlands) and was founded in 2012. As a contract development and manufacturing organization (CDMO), HALIX is licensed for the contract manufacturing of clinical and commercial medicines according to GMP standards. HALIX leverages advanced biopharmaceutical technologies and provides the full portfolio of pharmaceutical documentation of GMP production processes, as well as production of units which are required for clinical approval.
With HAL Allergy and the Droege Group at its side, HALIX is supported by two strong companies to secure financial stability and long-term focus.